These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 16358615)

  • 1. [Preventive surgical prcedures for inherited risk of breast cancer].
    Menke-Pluymers MB; Seynaeve C; van Geel AN; Klijn JG; Meijers-Heijboer EJ; Eggermont AM
    Ned Tijdschr Geneeskd; 2005 Nov; 149(48):2663-7. PubMed ID: 16358615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer.
    Kaas R; Verhoef S; Wesseling J; Rookus MA; Oldenburg HS; Peeters MJ; Rutgers EJ
    Ann Surg; 2010 Mar; 251(3):488-92. PubMed ID: 20134318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
    Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
    Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations.
    Fatouros M; Baltoyiannis G; Roukos DH
    Ann Surg Oncol; 2008 Jan; 15(1):21-33. PubMed ID: 17940826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation.
    Metcalfe KA; Foulkes WD; Kim-Sing C; Ainsworth P; Rosen B; Armel S; Poll A; Eisen A; Gilchrist D; Chudley A; Ghadirian P; Maugard C; Lemire EG; Sun P; Narod SA
    Clin Genet; 2008 May; 73(5):474-9. PubMed ID: 18341607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer.
    Narod SA
    Breast Cancer Res Treat; 2011 Jul; 128(2):581-3. PubMed ID: 21455666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.
    Eisen A; Lubinski J; Klijn J; Moller P; Lynch HT; Offit K; Weber B; Rebbeck T; Neuhausen SL; Ghadirian P; Foulkes WD; Gershoni-Baruch R; Friedman E; Rennert G; Wagner T; Isaacs C; Kim-Sing C; Ainsworth P; Sun P; Narod SA
    J Clin Oncol; 2005 Oct; 23(30):7491-6. PubMed ID: 16234515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
    Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA;
    J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventive surgery is associated with reduced cancer risk and mortality in women with BRCA1 and BRCA2 mutations.
    Domchek SM; Rebbeck TR
    LDI Issue Brief; 2010; 16(2):1-4. PubMed ID: 21545057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma.
    Shahedi K; Emanuelsson M; Wiklund F; Gronberg H
    Cancer; 2006 Mar; 106(6):1237-42. PubMed ID: 16475207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The carrier clinic: an evaluation of a novel clinic dedicated to the follow-up of BRCA1 and BRCA2 carriers--implications for oncogenetics practice.
    Bancroft EK; Locke I; Ardern-Jones A; D'Mello L; McReynolds K; Lennard F; Barbachano Y; Barwell J; Walker L; Mitchell G; Dorkins H; Cummings C; Paterson J; Kote-Jarai Z; Mitra A; Jhavar S; Thomas S; Houlston R; Shanley S; Eeles RA
    J Med Genet; 2010 Jul; 47(7):486-91. PubMed ID: 20472659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [INSERM-FNCLCC collective expertise. Recommendations for medical management of women with genetic risk of developing breast and/or ovarian cancer].
    Eisinger F; Alby N; Bremond A; Dauplat J; Espié M; Janiaud P; Kuttenn F; Lebrun JP; Lefranc JP; Pierret J; Sobol H; Stoppa-Lyonnet D; Thouvenin D; Tristant H; Feingold J
    Ann Genet; 1999; 42(1):51-64. PubMed ID: 10214508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newly diagnosed breast cancer patients choose bilateral mastectomy over breast-conserving surgery when testing positive for a BRCA1/2 mutation.
    Stolier AJ; Corsetti RL
    Am Surg; 2005 Dec; 71(12):1031-3. PubMed ID: 16447474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
    Roukos DH; Briasoulis E
    Nat Clin Pract Oncol; 2007 Oct; 4(10):578-90. PubMed ID: 17898808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy for breast cancer in BRCA1/BRCA2 carriers: clinical issues and management dilemmas.
    Pierce L
    Semin Radiat Oncol; 2002 Oct; 12(4):352-61. PubMed ID: 12382193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prophylactic mastectomy in women at high risk for breast and ovarian cancer: qualitative analysis of the decision making process and long-term satisfaction of two women carrying a BRCA1-mutation].
    Vodermaier A; Bauerfeind I; Untch M; Nestle-Krämling C
    Psychother Psychosom Med Psychol; 2006; 56(9-10):351-61. PubMed ID: 16804803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic.
    Heemskerk-Gerritsen BA; Brekelmans CT; Menke-Pluymers MB; van Geel AN; Tilanus-Linthorst MM; Bartels CC; Tan M; Meijers-Heijboer HE; Klijn JG; Seynaeve C
    Ann Surg Oncol; 2007 Dec; 14(12):3335-44. PubMed ID: 17541692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer susceptibility testing: past, present and future.
    Goldberg JI; Borgen PI
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1205-14. PubMed ID: 16925486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers.
    Palma M; Ristori E; Ricevuto E; Giannini G; Gulino A
    Crit Rev Oncol Hematol; 2006 Jan; 57(1):1-23. PubMed ID: 16337408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.